Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy
DA Morgenstern, S Baruchel… - Journal of pediatric …, 2013 - journals.lww.com
More than half of the patients with high-risk neuroblastoma (NB) will relapse despite
intensive multimodal therapy, with an additional 10% to 20% refractory to induction
chemotherapy. Management of these patients is challenging, given disease heterogeneity,
resistance, and organ toxicity including poor hematological reserve. This review will discuss
the current treatment options and consider novel therapies on the horizon. Cytotoxic
chemotherapy regimens for relapse and refractory NB typically center on the use of the …
intensive multimodal therapy, with an additional 10% to 20% refractory to induction
chemotherapy. Management of these patients is challenging, given disease heterogeneity,
resistance, and organ toxicity including poor hematological reserve. This review will discuss
the current treatment options and consider novel therapies on the horizon. Cytotoxic
chemotherapy regimens for relapse and refractory NB typically center on the use of the …
